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Abstract The promise of science lies in expectations of
its beneWts to societies and is matched by expectations of
the realisation of the signiWcant public investment in that
science. In this paper, we undertake a methodological anal-
ysis of the science of biobanking and a sociological analy-
sis of translational research in relation to biobanking. Part
of global and local endeavours to translate raw biomedical
evidence into practice, biobanks aim to provide a platform
for generating new scientiWc knowledge to inform develop-
ment of new policies, systems and interventions to enhance
the public’s health. EVectively translating scientiWc knowl-
edge into routine practice, however, involves more than
good science. Although biobanks undoubtedly provide a
fundamental resource for both clinical and public health
practice, their potentiating ontology—that their outputs are
perpetually a promise of scientiWc knowledge generation—
renders translation rather less straightforward than drug
discovery and treatment implementation. Biobanking
science, therefore, provides a perfect counterpoint against
which to test the bounds of translational research. We argue
that translational research is a contextual and cumulative
process: one that is necessarily dynamic and interactive and
involves multiple actors. We propose a new multidimen-
sional model of translational research which enables us to
imagine a new paradigm: one that takes us from bench to
bedside to backyard and beyond, that is, attentive to the
social and political context of translational science, and is
cognisant of all the players in that process be they research-
ers, health professionals, policy makers, industry represen-
tatives, members of the public or research participants,
amongst others.
Introduction
Expectations of scientiWc research run high. Internationally,
funding bodies and government agencies have placed
increasing emphasis on the outcomes and impact of scien-
tiWc endeavour (Campbell et al. 2000; Cooksey et al. 2006;
Craig et al. 2008; Zerhouni 2003). The promise of science
lies in expectations of the beneWts bioscience can bring to
societies and is matched by expectations of the realisation
of the signiWcant public investment in that science. In
health research, the transformation of bioscience into socie-
tal beneWt is described in terms of translation. First reported
as such in the medical literature in 1993 the concept of
translational research has a much longer history (Antoine
1991). The increasing interest, especially recently, is
evident in even a cursory search of PubMed where citations
including the term ‘translational research’ have increased
nearly 200-fold since 1993, with more than half of these
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citations occurring in the past 2 years. Likewise, the use of
the term ‘bench to beside’ to describe the transformation of
bioscience into therapeutic practice, seen as early as 1985
(Merz 1985), has exploded across the biosciences. In addi-
tion, therein lies a conundrum for translational research in
biobanking.
Population biobanks represent an ontologically distinct
approach to knowledge generation when compared with the
dominant scientiWc forms envisaged by translational
research. Population biobanks merge the promise of
genomics with foundational public health science, includ-
ing classical epidemiology (Khoury et al. 2009a, b), princi-
pally in the form of population-based cohort studies
(Burton et al. 2010; P3G Observatory 2009). Biobanking
science is implicitly oriented to the population focus of its
historical epidemiological forebears as well as to the indi-
vidualist focus of contemporary genomic medicine. Bio-
banking steers away from the hypothesis testing that is
fundamental to much basic and applied bioscience; i.e.
genome-wide association studies (GWAS) and clinical tri-
als, respectively. Instead, it embraces methods of knowl-
edge generation which prepare us to ask questions we may
not yet be able to formulate. Extensive work has already
been undertaken (Knoppers et al. 2008) to reWne the design
(Burton et al. 2009; ISBER 2005; Moore et al. 2011; Wal-
lace et al. 2009), management (Borugian et al. 2010; Litton
et al. 2003; Peakman and Elliott 2008; Yuille et al. 2008)
and harmonisation (Fortier et al. 2010; Stover et al. 2010;
Wichmann et al. 2011) of biobanking platforms and to pro-
mote and facilitate liberal data access (P3G Consortium
et al. 2009; Wolfson et al. 2010).
However, biobanks and data are not ends in themselves.
Part of global and local endeavours to translate raw bio-
medical evidence into practice, their purpose is to provide a
platform—composed of high quality data and samples—
that can later provide a Wrm foundation for generating new
scientiWc knowledge to inform development of new poli-
cies, systems and interventions to enhance the public’s
health (Davey Smith et al. 2005; Khoury et al. 2009a).
EVectively translating scientiWc knowledge into routine
practice, however, involves more than good science. It is a
complex social process that necessarily involves scientists,
health professionals, policy makers, funders, industry and
members of the public (including research participants); i.e.
it is about the people not just the science. Moreover, the
mechanisms of successful translation are not well enough
understood. Drawing on a range of disciplinary perspec-
tives, including biomedical and public health science,
social science and philosophy, we overview the scientiWc
logics underpinning the creation of biobanks and describe
what translation might mean for population biobanking
research. We argue that if the future utility of population
biobanking is to be optimised we must explore what we
should be doing now to ensure extension of the transdisci-
plinary collaborations to include, for example, health policy
makers so that biobanking resources are conWgured with
translational aims in mind. This will help ensure that bio-
banks can best contribute to the evidence-base for health
policy decision-making, health-care commissioning and the
implementation of new initiatives in practice.
Population biobanking science
The generation of scientiWc knowledge involves the asking
and answering of questions within constraints imposed by
contemporaneous needs, knowledge and technology. Until
recently, most deWnitive answers in health science per-
tained to factors with relatively large eVects—e.g. Lind’s
demonstration that citrus fruit prevents scurvy (Kirch
2008); the causal role of smoking in many diseases (World
Health Organisation 2008); the impact of monogenic
genetic variants causing major diseases such as Hunting-
ton’s chorea and cystic Wbrosis (Carter 1977). Recent years,
however, have seen a fundamental change in the nature of
biomedical investigation. Modern bioscience reXects the
disease priorities of contemporary societies—particularly
those of the ‘High Income Countries’ that primarily fund
that research. There is therefore a manifest focus on the
aetiological architecture of the common chronic diseases
that aVect these societies (Merikangas and Risch 2003; Prit-
chard and Cox 2002). The aim is to understand, and ulti-
mately intervene in, the complex causal pathways via
which genes and environmental/lifestyle/social determi-
nants act alone and in interaction to cause diseases and to
inXuence how those diseases progress once they have
developed (Khoury et al. 2009b; Merikangas and Risch
2003).
This new challenge demands a comprehensive explora-
tion of gene networks, of much weaker main eVects (Mano-
lio et al. 2008; Merikangas and Risch 2003; Wellcome
Trust Case Control Consortium 2007) and of interactions
between genetic, environmental, behavioural and social
factors (Manolio et al. 2006). Typically, the aim is to iden-
tify and quantify the impact of a number of small eVects
(genetic, socio-environmental or a combination) on a given
disease or health-related trait, but to do this the eVects of
the determinants of interest must Wrst be disentangled from
an obscuring cacophony of aetiological noise resulting
from many other causal determinants. The modern search
for the risk factors of complex diseases has often been com-
pared to Wnding a needle in a hay-stack (Moore et al. 2010),
but this simile should probably be extended to note that the
needle itself is made of straw.
The change in focus from investigating risk factors with
relatively large eVects to explore networks of risk factorsHum Genet (2011) 130:333–345 335
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with weak eVects requires a radically diVerent approach.
This is because many of the eVects are very weak: for
example, although the relative risk of lung cancer in smok-
ers versus non-smokers is of the order 9.0 (Doll and Hill
1952,  1964), most known associations between genetic
variants and chronic diseases reXect weak eVects with typi-
cal allelic odds ratios in the range of 1.1–1.4 (Burton et al.
2009; Spencer et al. 2009; Zondervan and Cardon 2007).
Critically, eVects as weak as this not only provide an obvi-
ous challenge from the perspective of statistical power
(Burton et al. 2009) but, in addition, they can easily be cre-
ated or concealed by confounding or reverse causality. In
fact, these latter concerns led Gary Taubes to claim that
observational epidemiology had already reached its infer-
ential limits (Taubes 1995).
There is no doubt that useful scientiWc inferences can be
generated in such settings, but the obvious route to new
knowledge would involve well-designed experiments: care-
fully controlled experiments in the laboratory setting, or
studies involving randomised allocation of intervention as
in a conventional clinical trial. Such experiments can
negate confounding. However, many research questions in
human health are simply not amenable to an experimental
approach. It is, therefore, fortunate that despite the very real
concerns raised by Taubes (1995), useful inferences on
weak eVects can sometimes be based on observational stud-
ies.
Although genetic variants cannot be allocated randomly
as part of an experiment—they are allocated randomly at
conception (Davey Smith 2006; Davey Smith et al. 2005).
SpeciWcally, if one of your parents has two diVerent alleles
at a particular locus, you must receive one, and only one, of
them (Burton et al. 2005). Furthermore, the particular allele
that is actually transmitted is randomly determined in a
manner that is entirely independent of the variants that are
inherited at all other loci (from either parent), with the spe-
ciWc exception of those few loci that are in close linkage
disequilibrium (LD) (Clayton and McKeigue 2001; Cordell
and Clayton 2005) on the same chromosome. This process
forms the basis of what is often known as Mendelian ran-
domisation (MR) (Davey Smith 2006; Davey Smith and
Ebrahim 2003; Sheehan et al. 2008) which has a number of
profound implications: (i) genetic variants do not usually
confound one another unless they are in close LD (here we
ignore the inferential distortion that can arise from ancestral
substructure in an imperfectly designed study; Devlin et al.
2001). (ii) Genetic variants are not generally associated
with socio-environmental determinants (and cannot there-
fore confound them) unless a particular genetic variant has
a biological mechanism that directly modiWes exposure to a
socio-environmental determinant of interest. In other
words, which of two alleles is received at conception from
one parent cannot possibly be related to whether an individ-
ual later chooses to smoke—unless those two alleles have a
diVerent and direct impact on their predilection to smoke. In
general, therefore, inferences on genetic determinants are
not confounded by environmental factors and vice versa.
(Clayton and McKeigue 2001; Davey Smith 2006; Davey
Smith and Ebrahim 2003; Davey Smith et al. 2005; Shee-
han et al. 2008). (iii) Interactions between socio-environ-
mental determinants and genes are typically more robust to
confounding than are the direct eVects of the socio-environ-
mental determinants themselves. For example, in relation to
the role of a gene (G) and a socio-environmental determi-
nant (SE) in causing a disease (D), serious confounding of
the direct eVect of SE could easily arise if confounding fac-
tor C was associated both with D and with SE and such con-
founding is extremely common because health-related
behaviours tend to cluster (Davey Smith et al. 2005; Ebra-
him et al. 2004): e.g. smokers often take less exercise, drink
more alcohol, and take fewer vitamins. This is why it was
argued that observational studies have a limited role in rela-
tion to studying weak eVects (Taubes 1995). But, if scien-
tiWc interest focuses on the interaction between G and SE
(G:SE)—i.e. does the impact of SE vary diVerentially with
genotype at G?—inferences are markedly less sensitive to
conventional confounding as described above. It is true that
serious inferential problems will arise if the nature of the
G:SE interaction varies systematically with the level of C,
but this is markedly less likely than the near ubiquitous
clustering of health-related behaviours (Davey Smith et al.
2005; Ebrahim et al. 2004). (iv) Items i, ii and iii imply that
weak eVects associated with genetic variants or with inter-
actions between genes and socio-environmental determi-
nants are of considerably greater inferential value than
would be the case in the absence of MR (Taubes 1995).
However, Mendelian randomisation also provides a Wrm
inferential foundation when scientiWc interest focuses on the
direct eVect of an environmental exposure alone. In fact this
is the very purpose to which MR has classically been
applied (Clayton and McKeigue 2001; Davey Smith 2006;
Davey Smith and Ebrahim 2003; Davey Smith et al. 2005;
Sheehan et al. 2008; Timpson et al. 2005). SpeciWcally, if
one is interested in whether factor SE protects against dis-
ease D, if one can identify a genetic variant (G*) that has
the same impact on an individual as increased (or
decreased) exposure to SE, then demonstration that G* is
associated with D provides evidence that SE is causally
associated with D. This is known as an “instrumental vari-
able” approach (Davey Smith et al. 2005; Didelez and
Sheehan  2007; Sheehan et al. 2008). Crucially, although
this approach negates both confounding and reverse causal-
ity, a number of key assumptions that demand proper under-
standing of the underlying biology and mathematics must
be met (Didelez and Sheehan 2007; Palmer et al. 2008;
Sheehan et al. 2008).336 Hum Genet (2011) 130:333–345
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In addition, if enough is known about the underlying
biological, environmental and social determinants and if
adequate resources can be invested in measuring relevant
factors extremely carefully, it will sometimes be possible to
control the analysis closely enough to enable inferences to
be drawn that may reasonably be viewed as robust to con-
founding. Furthermore, if such an analysis is undertaken as
part of a prospective cohort study (with initial exposure
assessments being made whilst participants are still
healthy) reverse causality is far less likely to be a serious
problem. As we learn more and more about the underlying
biology and social science, our ability to address confound-
ing in ways that use prior knowledge in concert with
sophisticated analysis based on the data from very compre-
hensive databases will inevitably increase.
If they are used cautiously and appropriately, it is there-
fore clear that large observational epidemiological studies
can provide a useful basis for investigation of the causal
architecture of complex diseases. However, it is also clear
that these studies must be designed, set up and managed
strategically (BBMRI 2010; Knoppers et al. 2008; Knop-
pers and Kent 2006). This need was reXected in the deci-
sion to include European Biobanking and Biomolecular
Resources amongst the 36 designated priorities in the
ESFRI Roadmap that represented the European Union’s
strategy for development of the infrastructure supporting
pan-European science (European Strategy Forum on
Research Infrastructures 2006). In eVect, biobanks are now
seen as the infrastructural equivalent of linear accelerators
and telescope arrays in the physical sciences: that is, multi-
purpose facilities representing broad-based platforms to
support the scientiWc community as a whole in its asking
and answering of key questions across the realm of biosci-
ence. However, if their value is to be optimised, these facil-
ities must have a number of pivotal characteristics:
1. They must provide access to data and biosamples relat-
ing to vast numbers of individuals (Burton et al. 2009;
Collins 2004; Khoury 2004; Spencer et al. 2009; Zon-
dervan and Cardon 2007). Case–control studies includ-
ing thousands of cases are required even when interest
focuses on the most straightforward situation: the
detection of simple associations between single nucleo-
tide polymorphisms (SNPs) (Burton et al. 2005) and a
disease of interest (Burton et al. 2009; Spencer et al.
2009; Zondervan and Cardon 2007). Furthermore,
when, as is likely, scientiWc emphasis moves on to
focus on the study of gene–socio-environment and
gene–gene interactions, and the exploration of causal
pathways more comprehensively, tens of thousands of
cases will often be required (Burton et al. 2009). Tens
of thousands of participants can also be required to
study a quantitative phenotype (e.g. measured blood
pressure), because allelic eVect sizes may be as small
as 1/10th of a standard deviation, or even less (New-
ton-Cheh et al. 2009a; Repapi et al. 2009). Finally, the
use of an instrumental variable approach to address
confounding increases the sample size requirement still
further (Clayton and McKeigue 2001).
2.  Data and samples must be collected under formal stan-
dard operating procedures (Fortier et al. 2010; ISBER
2005; Moore et al. 2011), and the assessment of disease
status, biomarkers, physiological processes and social
and environmental factors must be both accurate and
precise. When aetiological eVects are already weak,
measurement error can substantially reduce statistical
power yet further (Burton et al. 2009; Wong et al.
2003), and if errors are made in assessing confounders,
real causal relationships may be obscured or artefacts
created.
3. To achieve sample sizes of the magnitude required—
i.e. involving enough participants that each have high
quality data and samples of the nature required—it will
often be necessary to pool data across multiple studies
(Burton et al. 2009, 2010; Wichmann et al. 2011). This
is well-exempliWed by the large collaborative consortia
that have been responsible for much of the recent pro-
gress in human population genomics (Burton et al.
2007; Easton et al. 2007; Frayling et al. 2007; HindorV
et al. 2009; Newton-Cheh et al. 2009a, b; Saxena et al.
2007; Scott et al. 2007; Stacey et al. 2007; Zeggini
et al. 2007).
Collectively, these various requirements have led to the
development of a new Weld of endeavour in bioscience that
may be referred to as ‘biobanking science’. The many pro-
fessionals and researchers that work in this Weld include:
laboratory scientists, clinical scientists, epidemiologists and
statisticians, informaticians, ethico-legal experts and social
scientists. Although they each have their own specialist
areas of exploratory interest and expertise within the
broader Weld of biomedical science, they share a collective
focus on optimising the design, set up, harmonisation, net-
working and evaluation of the range of studies that are
sometimes called biobanks: “Organized collection[s] of
human biological material [e.g. blood, urine or extracted
DNA] and associated information stored for one or more
research purposes” (Burton et al. 2010). The studies that
fall under this umbrella primarily represent population-
based cohort studies, large case–control studies and tissue
repositories, but some cross-sectional studies and random-
ised controlled trials qualify as biobanks too (Burton et al.
2010; P3G Observatory 2009). Crucially, although many of
these studies were originally designed to support classical
“phenotype to genotype” science (e.g. nested case–control
studies), they also provide a platform for exposure-basedHum Genet (2011) 130:333–345 337
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investigation including “genotype to phenotype” or “geno-
type-based” (Burton et al. 2010) studies. This latter
approach uses exposure-based information (particularly,
genotype data) to identify informative population-subsam-
ples that, with consent, can be brought in for detailed addi-
tional investigation. Here, the vast size of modern cohort-
based biobanks—sometimes viewed as being scientiWcally
ineYcient—provides a great strength: even a genotype that
occurs as rarely as one in one thousand people, will be rep-
resented in Wve hundred participants in a population-based
biobank containing 500,000 participants such as UK Bio-
bank. In addition, when biobanks are eVectively catalogued
and harmonised (Burton et al. 2010; Fortier et al. 2010;
P3G Observatory 2009), the available sampling frame for
such studies can potentially be extended to several millions.
The structures and actors within biobanking science are
reXective of what is described within social studies of sci-
ence as Mode 2 knowledge production; that is, a new way
of thinking about the generation of knowledge in science
(Nowotny et al. 2001, 2006). Mode 2 knowledge produc-
tion is carried out in the context of application (research
translation), brings a heterogeneity of skills and expertise to
the problem solving, and is transdisciplinary in nature
(Nowotny et al. 2001). Transdisciplinarity is not simply
another of the proliferation of terms for multidisciplinarity,
but rather points to the transgressive character of knowl-
edge generation (Nowotny et al. 2001) that there is a co-
evolution or co-production (Callon et al. 1992; Callon
1999, p. 69; JasanoV 2004, p. 70; Geels 2005) of knowl-
edge that transgresses disciplinary boundaries. Thus, it reX-
ects the intersection and co-evolution of disciplines.
Transdisciplinarity requires actors to engage actively in the
messy and thorny work of overcoming diVerence and awk-
wardness whilst also drawing strength and value from the
very existence of those diVerences (Demir 2008,  2011).
Demir (2011) demonstrates how scientists achieve transla-
tion of their work across disciplinary borders by extending
their own concepts and working language to incorporate
new concepts; much as in second language acquisition.
Through informal and formal exchanges, scientists in one
discipline acquire, albeit in a limited way, the language,
ideas and practices of another group (Demir 2011). Integra-
tion of these borrowed concepts and practices reshape the
frameworks of the adopting discipline or Weld; which
might, for example, facilitate harmonisation and data shar-
ing. Within biobanking, there is clear evidence not only of
transdisciplinary structures, but of the transdisciplinary
generation of knowledge. An ongoing ethnographic study
(Hammersley and Atkinson 2007) of the development of
DataSHIELD (Wolfson et al. 2010) by authors of this paper
(M.M., P.B.) demonstrates how the intersection of ethics,
informatics and statistics is shaping the structure of the
ensuing technology that is DataSHIELD.
The rapid progress of biobanking science over the last
5 years reXects a successful professional networking of bio-
banking scientists across the world that has been led by
organisations, institutions and projects such as: P3G (Knop-
pers et al. 2008), PHOEBE (Wolfson et al. 2010), BBMRI
(Wichmann et al. 2011), GEN2PHEN (2010), BioSHARE-
eu (2011), ISBER (2005), and NCI (Moore et al. 2011).
Crucially, the work carried out by these complementary and
overlapping groups has, to date, focussed primarily on
designing and setting up biobanks and on exploring a vari-
ety of approaches to networking and harmonisation (Boru-
gian et al. 2010; Burton et al. 2009; Fortier et al. 2010;
ISBER 2005; Litton et al. 2003; Moore et al. 2011; Peak-
man and Elliott 2008; Stover et al. 2010; Wallace et al.
2009; Wichmann et al. 2011; Yuille et al. 2008). However,
the scientiWc focus is now entering a new phase in which
the priorities are to provide liberal, but secure, access to
data and samples (Pisani and AbouZahr 2010; Walport and
Brest 2011), to ensure that biobanks are used widely and
eVectively, and to streamline pooled analysis involving
multiple biobanks (Fortier et al. 2010; Wolfson et al. 2010).
The success of the large transdisciplinary organisations
that comprise international biobanking is in no small part
due to the fact that the science underpinning the successful
construction and use of biobanks is philosophically very
diVerent from that underpinning hypothesis-based science.
Although biobanks are undoubtedly a child of contempo-
rary bioscience and are aimed primarily at facilitating new
scientiWc discoveries, they are not hypothesis-driven per se.
Rather, they may be seen as being part of a pre-competitive
endeavour on the part of many bioscientists to advance and
facilitate future hypothesis-driven science. In consequence,
although biobanks are costly and may take many years to
mature to full value, they should not be viewed as competi-
tors to hypothesis-based science. Rather they should be
viewed as enablers—i.e. an essential pre-requisite if
hypothesis-based research is to be as successful at disentan-
gling the causal structures underpinning complex diseases
as it has historically been at revealing the impact of much
stronger determinants of health and disease. In essence,
biobanks will ensure a Xexible yet valid platform for the as
yet unpredicted (and unpredictable) bioscience questions of
tomorrow. This not only impacts on the scientiWc design of
biobanks, but it has major ethico-legal and social implica-
tions. How, for example, can we eVectively ask participants
to consent to answer detailed questionnaires, provide inva-
sive tissue samples and agree to long-term monitoring of
their health when even the scientists do not know how all of
the data and samples will be used in the future? Of course,
one possible answer to this, seemingly rhetorical, question
is to ‘ask them’.
There can be little argument, but that the development of
biobanking science over the Wrst decade of the new338 Hum Genet (2011) 130:333–345
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millennium has been remarkable. Although it may be of
great interest and reward to the scientists involved, no part
of bioscience can ever be an end in itself. Society invests
heavily in scientiWc research related to medicine because it
is assumed that this will ultimately improve the health of
the community and of individuals within that community
(Cooksey et al. 2006; Martin et al. 2008). The raison d’etre
of biomedical research is therefore to enhance public health
through primary prevention, improved diagnosis and treat-
ment, and the enhanced long-term control of chronic dis-
eases. Such ends may be achieved via a wide range of
diVerent interventions at either the individual or population
levels and biobanks can undoubtedly make a pivotal contri-
bution to these aims. But if biobanks are to achieve optimal
utility in the long term, it is critical that extensive thought is
now put into how we should build on the successes of bio-
banking science to date, to ensure that biobanks are able to
provide eVective translational return in the future. The
transdisciplinary collaborations must be extended to
include professionals in public health, health policy making
and health economics. In addition, we should consider the
embedding of biobanks into health care systems. This will
facilitate the enrichment of biobank databases with popula-
tion-based and hospital-generated health event data. It will
also enhance the future potential for biobank-driven trans-
lational activity; particularly, translation into population
level public health. It is these issues that provide the focus
for the remainder of this paper.
Translational research: transforming data 
into knowledge and knowledge into practice
Demonstrating what has been described as a shift from
regimes of truth to regimes of hope in clinical and biosci-
ence (Moreira 2009; Moreira and Palladino 2005)—that is,
the speculative potential of new therapeutic interventions—
discussion of translational research begins in earnest with
the NIH roadmap (US) (Zerhouni 2003), Cooksey report
(UK) (Cooksey et al. 2006) and MRC framework for com-
plex interventions (UK) (Campbell et al. 2000; Craig et al.
2008). The NIH describes translational research as includ-
ing two areas of translation. “One is the process of applying
discoveries generated during research in the laboratory, and
in preclinical studies, to the development of trials and stud-
ies in humans. The second area of translation concerns
research aimed at enhancing the adoption of best practices
in the community” (NIH 2011). That is, bench to bedside
and research into practice. Called T1 and T2 translational
research, respectively, we can think of these endeavours as
the processes and practices of transforming data into
knowledge and knowledge into practice. The Cooksey
report identiWed two gaps in research, “the Wrst gap arises in
the translation of basic and clinical research into ideas and
products”, i.e. at the bench; “the second gap relates to intro-
ducing those ideas and products into clinical practice”, i.e.
at the bedside (Cooksey et al. 2006). Whilst the NIH areas
of translation describe a transition from the bench to the
community,  the backyard, it is gaps in T1 translational
research, from bench to bedside, that are the predominant
focus of the translational research literature and funding
(Woolf 2008). Thus, the long standing viewpoint of the bio-
medical lens, which more often includes the individual than
the population, is maintained (Murtagh and Hepworth
1997; Thomson et al. 2005). Nonetheless, just how these
translational transitions might be bridged has been the sub-
ject of much discussion, though there is a paucity of empir-
ical research on these processes. What is clear, however,
even in the seemingly most straightforward of translational
processes, for example from biomarker to drug discovery to
testing to adoption in routine clinical practice, is that it is
not suYcient to simply throw the outputs of science “over
the wall” (Cox 2011). That is, without aim, direction, pur-
pose and without communication on either side between
scientists, clinicians and others involved in disseminating
and implementing that science. There is recognition within
the bioscience community that translational research pre-
sents challenges and that the translational research model as
initially described does not adequately account for the
range of activity within bioscience or for the embeddedness
of bioscience in and with other disciplinary, professional or
public groupings and settings. Early appeals for the
involvement of a range of disciplines envisaged an expan-
sion to include biomedical and informatics scientists with
bioscience (Zerhouni 2003,  2005). More recent expecta-
tions reXect what social studies of science describe as com-
munities of promise (Martin et al. 2008) in which the
articulation of clinical and biosciences are fundamental to
the dynamics of translation and innovation and include the
involvement of social, behavioural and ethico-legal disci-
plinary contributions (Khoury 2010; Khoury et al. 2009b,
2011; Zimmern and Brice 2009) as well as public and par-
ticipant engagement in translational research, especially in
the knowledge to practice phase (Armstrong et al. 2006;
Graham and Tetroe 2007; Khoury et al. 2007). The impor-
tance of such contributions has been demonstrated empiri-
cally (Löwy 1996).
Elaborations of the NIH/Cooksey model have largely
included disambiguation of the T2 phase. Westfall et al.
(2007) argue for an expanded conception of the NIH trans-
lational research “roadmap” to ameliorate the “myriad
detours, speed traps, roadblocks, and potholes [that] limit
the movement of treatments from bench to practice” i.e. the
limited external validity of randomised controlled trials, the
diversity of health care practice eYciency and eVective-
ness, limited successful collaboration between researchers,Hum Genet (2011) 130:333–345 339
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clinicians and patients and failure to address the identiWed
needs of the community. They expand translational
research to incorporate T1–T3 components: where T1 rep-
resents translation to humans of basic science in the form
of preclinical and animal studies; T2 incorporates transla-
tion to patients of research through guidelines develop-
ment, meta-analyses and systematic reviews; and, in T3 the
translation to practice via dissemination and implementa-
tion research (Westfall et al. 2007). To address “mounting
expectations” of genomic medicine Khoury and colleagues
describe a T1–T4 continuum to “accelerate appropriate
integration of human genome discoveries into health care
and disease prevention” (Khoury et al. 2007). In the context
of the hoary debates regarding population impact (public
health) and individual outcomes (personalised medicine) of
genomic discovery, Burke et al. (2010) have most recently
added a T0 pre-scientiWc phase in a T0–T4 model to repre-
sent the context of population health needs. The T0 phase
represents assessment of the population health-disease bur-
den (Burke et al. 2010) which prompts (whether formally
or informally) T1 translational research that aims to move
scientiWc discovery into candidate applications. Evaluation
of candidate applications (treatments and other health inter-
ventions) in T2 translational research assesses these appli-
cations and shapes development of evidence-based
guidelines and policy. T3 translational research aims to
move  evidence-based recommendations and policy into
health care practice via implementation, dissemination and
diVusion research. Phase four, T4 translational research
aims to evaluate the health impact of the application in
practice. And thus the cycle begins again albeit, we hope,
with a modiWed population health-disease burden.
Though not addressing the T1/T2 model explicitly, the
recent review by Green and Guyer (2011) references a dis-
articulation of the T1 phase. Describing translation in
genomics as moving from base pairs to the bedside, Green
and Guyer (2011) add understanding of “the structure of
genomes”, the “the biology of genomes” and “the biology
of disease” to the T1 model. A molecular, cellular and
somatic disease model implied by Green comprise what we
call the T1.1, T1.2, T1.3 components of the T1 phase (see
Fig. 1). Added to this, we include T1.4, the understanding
of the social context and determinants of disease: this may
be in terms of the social construction and experience of the
disease itself (cf. Murtagh and Hepworth 2003), under-
standings of the social context of disease to inform new
interventions in the T2 setting (cf. Farnworth et al. 2008),
or population level studies of disease determinants. As we
state above, understanding of the social, behavioural and
ethico-legal dynamics are fundamental to successful imple-
mentation and improvement science. Also missing from
current models of translation is an explicit acknowledgment
of the tools and methodologies that underpin translation of
basic and applied research: for example, innovative theo-
ries, tools and methods for analysing data to maintain pri-
vacy and conWdentiality (Wolfson et al. 2010); evaluating
the appropriateness of interventions (Murtagh et al. 2007);
enhancing the processes of knowledge translation and
exchange (Graham and Tetroe 2007; Kitson AS 2009);
improving practice (Dixon-Woods et al. 2001); implement-
ing policy guidelines and new practice in complex organi-
sations (May 2006; May et al. 2009) and other approaches
of implementation and improvement science. We call these
Ttm or, T0tm, T1tm, and T2tm as appropriate to the phase of
translation (see Fig. 1). In terms of T2tm, we address some
of these approaches below.
As much as we cannot simply throw the science “over the
wall” and expect the generation of appropriate interventions,
nor can we simply throw these interventions “over the wall”.
Whilst the models of translational research above have been
elaborated beyond the dyadic T1 and T2 translational
research, concern with the processes by which knowledge is
translated into practice in the real world—that is, the messy,
contingent, ambiguous, peopled world—have been taken up
by a range of disciplines under the rubrics dissemination,
implementation, and most recently, improvement science,
i.e. T2tm. The important distinction between research trans-
lation and these variants of implementation/improvement
science is the focus of the former on the content of the sci-
ence and form of the interventions generated and of the latter
Fig. 1 An expanded transla-
tional research continuum 
(1 term used by Burke et al. 
2010; 2 derived from Green and 
Guyer 2011, 3 terms used by 
Khoury et al. 2007)340 Hum Genet (2011) 130:333–345
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on the processes of moving the resultant science and inter-
ventions across the research translation continuum into
practice. Key amongst these approaches is knowledge trans-
lation (KT) which is deWned by the Canadian Institute for
Health Research (CIHR) as “a dynamic and iterative process
that includes synthesis, dissemination, exchange and ethi-
cally sound application of knowledge to improve the health
of Canadians, provide more eVective health services and
products and strengthen the health care system” (CIHR
2011). With adjustments for citizenship this is the deWnition
used in the international literature and in the Canadian con-
text goes under the banner ‘better research, better decisions,
better health’. KT has an inherently democratising orienta-
tion. KT draws upon a long history within health promotion,
health education and community development of engaging
communities, health care providers and policy makers with
health care issues, action and change. These multiple per-
spectives share a common understanding of the translation
of knowledge to practice as a complex dynamic social pro-
cess. Moreover, these are public, not simply scientiWc
issues. As with Nowotny et al.’s (2001, 2006) call for trans-
disciplinary knowledge generation, the forums for discus-
sion and development of the translation of biobanking
knowledge necessarily involve the representation and partic-
ipation of scientists with industry, government and health
service stakeholders as well as research participants and the
public. Being neither the expert forums of academic confer-
ences, select committees and health department committee
meetings nor the public forums of patient groups, public
meetings and demonstrations, these are, instead, what Cal-
lon et al. (2009) describe as hybrid forums. Translation of
biobanking science demands the active involvement and
intersection of perspectives of the full range of stakeholders:
that is, the co-evolution of translational research.
Knowledge translation under the CIHR deWnition “takes
place within a complex system of interactions between
researchers and knowledge users which may vary in inten-
sity, complexity and level of engagement depending on the
nature of the research and the Wndings as well as the needs
of the particular knowledge user” (CIHR 2011). KT oVers a
number of strategies of translation and exchange, the pri-
mary mode of which is a knowledge-to-action framework,
which incorporate cycles of development that iterate
between problem identiWcation, knowledge synthesis, con-
textualising, tailoring and adapting knowledge, product and
tools development, and evaluating and sustaining knowl-
edge use (Graham and Tetroe 2007; Kitson and Straus
2009). Practices of KT include: use of consensus confer-
ences or expert panels, systematic reviews, narrative syn-
theses, meta-analyses, meta-syntheses and practice
guidelines to contextualise and integrate research Wndings;
dissemination via brieWngs and educational sessions with
stakeholders, including patients, practitioners and policy
makers, engaging knowledge users in developing and exe-
cuting dissemination/implementation plans, and media
engagement; knowledge exchange through interaction
between knowledge users and researchers and results in
mutual learning through the process of planning, produc-
ing, disseminating, and applying existing or new research
in decision-making; and, are consistent with ethical princi-
ples and norms, social values, as well as legal and other
regulatory frameworks (Kitson and Straus 2009). Empirical
studies of KT strategies demonstrate their promise, but also
their challenges (Löwy 1996; Mitton et al. 2009; Mitton
et al. 2007) and such networks demand the reshaping of
some members’ normative cultures and beliefs. In one
example, the processes were inclusive and facilitated the
involvement of non-academic actors, but tended to conceal
political tensions (Lehoux et al. 2008). The resultant sci-
ence was a pragmatic one whose intention was not to pro-
vide a critique or to produce unconventional knowledge
(Lehoux et al. 2008); a civilised science (Lehoux et al.
2008). Although we must guard against an untrammelled
science, an overly civilised science runs the risk of quash-
ing innovation. Limits may impede bioscientiWc creativity
and imagination but the challenges oVered by transdiscipli-
narity can become a driving force for creativity (Nowotny
2008). As in biobanking science, the challenges of ethico-
legal scholars (Cambon-Thomsen et al. 2007; Gottweis and
Lauss 2010; Hoeyer 2008; Knoppers and Chadwick 2005)
related to privacy and security of data have led to develop-
ment of new technologies (Wolfson et al. 2010).
Studies of implementation suggest a range of challenges
to moving new bioscience knowledge into practice. Kitson
and Straus (2009) demonstrate inherent resistance in many
organisations to embrace change and that most people
(including professionals) operate most of the time on ‘auto-
matic pilot’ and will unconsciously adapt to worsening con-
ditions or tolerate diminishing standards. Denis et al.
(2007) identiWes the organisational components as neces-
sary for KT and implementation—knowledge as: capabili-
ties (support to use and diVuse knowledge, e.g. knowledge
brokers, training); process (e.g. knowledge networks, com-
munities of practice, integration of KT in research); and
codiWcation (e.g. practice guidelines, quality indicators,
performance management systems). Normative Process
Theory (May 2006; May et al. 2009) suggests that interven-
tions only become routinely embedded (implemented and
integrated) in their social, organisational and professional
contexts as the result of people working, individually and
collectively, to do so. Successfully achieving this requires
an understanding of: how people make sense of the
action(s) to be implemented; their attitudes; and their inten-
tions. Importantly, implementation requires “continuous
investment by people in ensembles of action that carry for-
ward in time and space” (May et al. 2009).Hum Genet (2011) 130:333–345 341
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Research translation is a contextual and cumulative
process: one that is necessarily dynamic and interactive;
one that involves multiple actors. Research translation is
broadly conceived as one in which there is a contemporane-
ous “exploration of new avenues of research occurring in
the same contexts in which new interventions are being
developed and applications anticipated” (O’Malley and
Stotz 2011). Interventions are ideally part of an iterative
cycle of translation, incorporating further intervention and
reintegration. Implementation/improvement science is
predominantly focused on the T2 (i.e. T2–T4) phases of the
translational research continuum. Arguably, in biobanking
science, the methods of KT as described here are necessary
across the continuum to include T0tm and T1tm methodolo-
gies to complete and maintain the cycle of translation.
What is not yet entirely clear is just how to operationalise
the translation cycle. Certainly knowledge generation will
be collaborative, interactive and transdisciplinary. Practical
methodologies of translation (including KT) in biobanking
will likely include collaborative multiple stakeholder
networks (hybrid forums) to build on the existing
transdisciplinary science networks.
Addressing the complexity of bioscience knowledge gen-
eration and its implementation is crucial for robust under-
standings of translational research. This is arguably more so
for biobanking science. Whilst biobanks undoubtedly pro-
vide a fundamental resource for both clinical and public
health practice their potentiating ontology—that their out-
puts are perpetually a promise of scientiWc knowledge gen-
eration (Borup et al. 2006; Brown and Michael 2003; Martin
et al. 2008)—renders translation rather less straightforward
than drug discovery and treatment implementation. Bio-
banking science therefore provides a perfect counterpoint
against which to test the bounds of thinking in terms of
knowledge generation and its translation. We must under-
stand translation more expansively to envisage how transla-
tional practice might be broadened. The beginnings of a
robust model are to be found across the range of consider-
ations of translational research and knowledge generation
described above, both from within bioscience and without.
Conclusion: translational research and the promise 
of biobanking science
In this paper, we described the distinctiveness of population
biobanking and deWned distinctions between a range of
disciplinary approaches to translation in/of research. That
we must imagine instead, for translational research for
biobanks, a new paradigm: one that takes us from bench to
bedside to backyard and beyond; that is attentive to the
social and political context of translational science; and is
cognisant of all the players in that process be they research-
ers, health professionals, policy makers, industry represen-
tatives or members of the public, amongst others. Although
the question of just how we achieve this remains open, it is
essential to direct our attention to these critical issues in the
current phase of biobank development. We have outlined
some key components here of an approach that requires fur-
ther development. We need to explore how we can ensure
that the maturing biobanks platforms are appropriately set
up to optimise their ultimate value as drivers of transla-
tional change. There is a vital need to embed biobanks
within health systems and to ensure involvement of policy
makers, and health care providers early in the process.
These developments will only succeed through coopera-
tion. The depth and breadth of information that is ulti-
mately required is so extensive that we will never have as
much as we might ideally like. Consequently, it is to every-
body’s advantage that biobank builders freely share their
knowledge and expertise. The long-term management and
use of data are social processes with ethico-legal implica-
tions. Much of the management of the science must focus
on these issues rather than on the detailed bioscience itself.
This demands the development and provision of new meth-
ods and tools, and the active co-involvement of bioscien-
tists, clinical scientists, population and public health
scientists, social scientists, and experts in information man-
agement and technology, and ethico-legal issues. To opti-
mise ultimate outcomes, it should also involve the general
public, health care providers and strategists, politicians and
industry. No single group can possibly do the work that is
required, and no single group can truly dominate or lead.
Optimising the translation of biobank science into societal
beneWt is necessarily a transdisciplinary project.
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